Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting

Area of Science:

• Nanomedicine
• Oncology
• Bioconjugation Chemistry

Background:

• Active cancer targeting leverages ligands on nanocarriers to recognize cancer-specific biomarkers.
• Nanoparticle (NP)-based systems offer large surface areas for ligand conjugation, enhancing targeting specificity over passive methods.
• Epidermal growth factor receptor (EGFR) is a key biomarker overexpressed in many cancers, making it a prime target for nanomedicine.

Purpose of the Study:

• To review recent advancements in anti-EGFR nanocarriers for targeted cancer therapy.
• To explore diverse conjugation strategies for functionalizing NPs with anti-EGFR ligands.
• To discuss characterization techniques for verifying NP-ligand conjugation.

Main Methods:

• Literature review of recent studies on anti-EGFR nanocarriers.
• Analysis of various conjugation chemistries for NP functionalization.
• Examination of characterization techniques for assessing conjugation.

Main Results:

• Nanocarriers functionalized with anti-EGFR ligands demonstrate specific tumor cell capture and receptor-mediated endocytosis.
• Diverse conjugation strategies exist, impacting the stability and efficacy of nanocarriers.
• Characterization methods confirm successful ligand attachment and conjugation patterns.

Conclusions:

• Anti-EGFR nanocarriers represent a promising strategy for targeted cancer therapy.
• Careful selection of conjugation chemistry is crucial for developing effective and stable nanomedicines.
• Further research into conjugation and characterization will advance nanocarrier-based cancer treatments.